Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029432001ex99-1.htm PRESS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR THE FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results NEWARK, NJ – June 11, 2026 (GLOBE NEWSWIRE) - Rafae
How this was made
The 30-second read
Why it matters
The newest actionable items are (1) completion of the last patient visit in the pivotal Phase 3 trial and (2) management’s expectation to submit the NDA in the second half of calendar 2026 after a pre-NDA meeting with the FDA. Financials show continued net losses and higher R&D expense tied to Cyclo consolidation, with cash at $30.5M as of April 30, 2026.
Market read
Traders may reprice the probability-weighted path to NDA submission/acceptance based on the Phase 3 completion milestone and stated 2H 2026 NDA timing, while monitoring cash runway and burn.
What to watch
Cash is $30.5M and R&D rose sharply due to Cyclo consolidation, increasing financing risk before NDA submission in 2H 2026.
Background
Rafael Holdings’ lead candidate Trappsol® Cyclo™ is in a pivotal Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 (NPC1). The filing is an 8-K with quarterly financial results and management commentary on regulatory next steps.
Ticker impact
Rafael Holdings reports Q3 FY2026 results and says it completed the last patient visit of its pivotal Phase 3 TransportNPC trial, targeting an NDA submission in 2H 2026.
Near-term sentiment likely improves on the Phase 3 completion and 2H 2026 NDA expectation, but dilution/burn concerns may cap upside given cash of $30.5M and higher R&D.
The article is a primary 8-K/press release with a concrete trial milestone and an FDA path statement, but it does not provide new efficacy/safety data or explicit guidance numbers beyond financials and cash.
Market effects
Highlights continued regulatory progress for rare-disease gene/biologic-like programs and reinforces the market’s focus on NDA timing after pivotal Phase 3 completion.
Limited; company-specific biotech update with no stated regional supply chain or financing event.
Moderate; NPC1 is global and FDA interaction can influence investor perception of similar rare-disease timelines.
Counterpoint
Phase 3 completion does not equal NDA acceptance or approval; investors may be over-weighting timeline certainty without new clinical readouts.
Key entities
- issuerRafael Holdings, Inc.
Reports Q3 FY2026 financial results and pivotal Phase 3 TransportNPC completion; expects NDA submission in 2H 2026.
- clinical_programTransportNPC™ trial
Pivotal Phase 3 study for Trappsol® Cyclo™ in NPC1; last patient visit completed per management.
- regulatorFDA
Pre-NDA meeting and ongoing collaboration referenced; management cites an expedited path forward.
